LAUSR

s Annals of Oncology progression and how it would impact their family and lives, the impact that mCRPC has on their daily, physical abilities (e.g. difficulty walking, muscle loss) and the impact a patients’ mCRPC has on the family and caregivers. Patients had high expectations from Ra-223 in terms of cessation of disease progression (32%) and pain alleviation (23%), but also worry about adjusting to the treatment. All 3 physicians cited the need for information sharing about Ra-223. Conclusions: The symptoms and impacts of living with mCRPC and the associated burden of bone metastasis and skeletal-related symptoms are considerable and varied, and information sharing is key to easing concerns in utilizing Ra-223 treatment. Legal entity responsible for the study: Bayer Yakuhin, Ltd. Funding: Bayer Yakuhin, Ltd. Disclosure: H. Uemura: Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: Janssen Pharmaceutical; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: Bayer Yakuhin, Ltd.; Honoraria (self), Speaker Bureau/Expert testimony: Astellas Pharmaceutical; Honoraria (self), Speaker Bureau/Expert testimony: Takeda Pharmaceutical; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: AstraZeneca Pharmaceutical. K. Akakura: Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Bayer Yakuhin, Ltd.; Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Astellas Pharmaceutical; Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Takeda Pharmaceutical; Speaker Bureau/ Expert testimony, Travel/Accommodation/Expenses: AstraZeneca Pharmaceutical; Speaker Bureau/ Expert testimony, Travel/Accommodation/Expenses: Janssen Pharmaceutical. A. Stroupe, C. Seo, A. Uzumcu, K. McCarrier: Advisory/Consultancy: Bayer Yakuhin, Ltd. D. Ledesma: Full/Part-time employment: Bayer Yakuhin, Ltd. All other authors have declared no conflicts of interest. https://doi.org/10.1016/j.annonc.2020.10.448